Items stated in the management plan
This document does not state the plan name, plan period, or numerical targets.
The purpose is to streamline the structure and optimize the allocation of management resources to priority areas in order to steadily advance research and development and generate results. In addition, this policy was adopted because cerebral palsy was redefined as the highest-priority indication in the cell therapy business and management resources would be strategically concentrated on this indication.
| Item | Details |
|---|---|
| Key initiatives | Policy of redefining cerebral palsy as the highest-priority indication in the cell therapy business and strategically concentrating management resources on this indication, Consolidate S-Quatre’s research and development functions and management resources at the Sapporo Research Institute, which has primarily undertaken research and development for this indication, and further strengthen research and development activities, The research functions of the Tokyo Lab will be integrated into the Sapporo Research Institute by the end of June 2026 |
| Reason for revision or withdrawal | The purpose is to streamline the structure and optimize the allocation of management resources to priority areas in order to steadily advance research and development and generate results. In addition, this policy was adopted because cerebral palsy was redefined as the highest-priority indication in the cell therapy business and management resources would be strategically concentrated on this indication. |
| Publication date | 30 March 2026 |
Items this document does not state (22)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The research and development structure will be streamlined and the allocation of management resources to priority areas optimized in order to steadily advance research and development and generate results. In addition, cerebral palsy will be redefined as the highest-priority indication in the cell therapy business, and management resources will be concentrated on it.